Clinical Scorecard: HERV-K EnvelopE RNA in Plasma: A Non-Invasive Biomarker for Diagnosing Lung Adenocarcinoma and Evaluating Prognosis Alongside Standard Serum Tumor Markers

At a Glance

Key Highlights

• HERV-K env mRNA is significantly upregulated in LUAD compared to LUSC and benign nodules.
• Plasma HERV-K env mRNA correlates with tissue expression and shows potential for early diagnosis.
• High plasma levels of HERV-K env mRNA are associated with poorer overall survival in LUAD patients.
• ROC analysis indicates excellent diagnostic performance for stage I/II LUAD.
• Conventional serum tumor markers show limited correlation with plasma HERV-K env mRNA levels.

Guideline-Based Recommendations

Diagnosis

• Consider plasma HERV-K env mRNA for subtype-specific diagnosis in lung cancer.

Management

• Utilize HERV-K env mRNA levels for prognostic assessment in LUAD.

Monitoring & Follow-up

• Monitor plasma HERV-K env mRNA levels for correlation with disease progression.

Risks

• High levels of plasma HERV-K env mRNA may indicate poorer prognosis.

Patient & Prescribing Data

Patients diagnosed with lung adenocarcinoma and non-small cell lung cancer.

HERV-K env mRNA may serve as a complementary biomarker alongside conventional serum tumor markers.

Clinical Best Practices

• Incorporate HERV-K env mRNA testing in diagnostic protocols for lung adenocarcinoma.
• Use plasma biomarkers in conjunction with imaging and histological assessments.

Related Resources & Content

• Study on HERV-K as a biomarker